Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Just Reported Increased Shorts

September 16, 2018 - By Anthony Romero

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Logo

The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) registered an increase of 4.75% in short interest. ARWR’s total short interest was 14.50M shares in September as published by FINRA. Its up 4.75% from 13.84M shares, reported previously. With 1.27M shares average volume, it will take short sellers 11 days to cover their ARWR’s short positions. The short interest to Arrowhead Pharmaceuticals Inc’s float is 20.24%.

The stock increased 3.16% or $0.58 during the last trading session, reaching $18.91. About 1.51 million shares traded. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 456.10% since September 16, 2017 and is uptrending. It has outperformed by 440.48% the S&P500.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $1.67 billion. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Coverage

Among 4 analysts covering Arrowhead Pharmaceuticals (NASDAQ:ARWR), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arrowhead Pharmaceuticals had 8 analyst reports since March 27, 2018 according to SRatingsIntel. The rating was maintained by FBR Capital with “Hold” on Tuesday, March 27. On Wednesday, May 9 the stock rating was upgraded by Cantor Fitzgerald to “Overweight”. Cantor Fitzgerald maintained Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) rating on Wednesday, May 30. Cantor Fitzgerald has “Buy” rating and $1300 target. FBR Capital upgraded the shares of ARWR in report on Thursday, September 6 to “Buy” rating. The firm earned “Buy” rating on Monday, June 18 by Cantor Fitzgerald. Chardan Capital Markets maintained it with “Buy” rating and $24.5 target in Thursday, September 6 report. The firm has “Neutral” rating by FBR Capital given on Wednesday, August 8.

More important recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on September 07, 2018, also Nasdaq.com published article titled: “Mid-Afternoon Market Update: Crude Oil Down 1.2%; Cloudera Shares Climb On Upbeat Earnings”, Seekingalpha.com published: “Arrowhead’s HBV candidate shows positive action in early-stage study; shares up 16% premarket” on September 06, 2018. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was released by: Seekingalpha.com and their article: “Arrowhead Pharmaceuticals Could Become The Next Gilead” with publication date: September 07, 2018.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.